Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.33 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.32 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6492682 | 0.82 | CYP3A4 (0.36) | MT-CO2RAB9ANR1H4 | |
| SCHEMBL6494236 | 0.80 | NPY2R (0.41) | KMT2AMEN1NR1H4 | |
| SCHEMBL6135389 | 0.79 | LMNA (0.45) | KMT2AMEN1RAB9ALMNAL3MBTL1 | |
| SCHEMBL6505131 | 0.79 | LMNA (0.45) | KMT2AMEN1NPSR1LMNAL3MBTL1 | |
| SCHEMBL28310488 | 0.78 | PAX8 (0.46) | BRD4PAX8MT-CO2CREBBPKMT2A | |
| SCHEMBL27606470 | 0.77 | HDAC3 (0.31) | MT-CO2KMT2AMEN1 | |
| SCHEMBL29004748 | 0.76 | HTR3E (0.51) | BRD4PAX8KMT2ANPSR1LMNA | |
| SCHEMBL30455057 | 0.76 | HTR3E (0.51) | BRD4PAX8KMT2ANPSR1LMNA | |
| SCHEMBL29276902 | 0.75 | TSHR (0.44) | BRD4PAX8MT-CO2CREBBPKAT8 | |
| SCHEMBL8018111 | 0.75 | PAX8 (0.55) | BRD4PAX8MT-CO2CREBBPKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6890934-B2 | Sulfonamide compounds and uses thereof as medicines | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-10 | — | — | US | disclosed |
| US-20030171396-A1 | Sulfonamide compounds and uses thereof as medicines | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-09-11 | — | — | US | disclosed |
| US-6573274-B1 | Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| CN-1335847-A | Sulfonamide compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-02-13 | — | — | CN | disclosed |
| EP-1136492-A1 | SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171396-A1 | Sulfonamide compounds and uses thereof as medicines | PDE2A, PDE3A, PDE5A | BRD4 2621/4885PAX8 2258/4885MT-CO2 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.